Apogee Therapeutics, Inc.
APGENASDAQ
USReal-Time Price
USReal-Time Price$135.07USD
0.00 (0.00%)Today
BTI Score
Near Future
50
Long Term
49
BTI Fair Market Cap
$1.38B
+508.71% vs fair
Biotechnology
High Risk
Apogee Therapeutics, Inc. (APGE) Stock Analysis
BTI's proprietary analysis of Apogee Therapeutics, Inc. (APGE): overall score, long- and short-term outlook, risk rating and fair-value verdict based on fundamentals, valuation and momentum.
Major-Firm Consensus
Hold
Filtered to 21 major global investment banks
Buy
6
Hold
15
Sell
0
Price Target Consensus
High
—
Consensus
$134.85
Low
—
Current
$135.07
Upside: -0.2%
Target Trend
Last Month— (0)
Last Quarter— (0)
Last Year— (0)
Ratings History — Major Investment Banks
| Firm | Rating | Action | Previous | Price Target | Upside | Date |
|---|---|---|---|---|---|---|
| Citi | Hold | Maintains | — | $135.00 | -0.1% | Aug 13, 2026 |
| Truist Financial | Hold | Maintains | — | — | — | Aug 13, 2026 |
| Canaccord Genuity | Hold | Reiterates | — | $135.00 | -0.1% | Aug 11, 2026 |
| Wedbush | Hold | Maintains | — | $135.00 | -0.1% | Aug 11, 2026 |
| RBC Capital | Hold | Maintains | — | $135.00 | -0.1% | Aug 10, 2026 |
| Stifel Nicolaus | Buy | Maintains | — | $133.00 | -1.5% | Jun 29, 2026 |
| Mizuho Securities | Hold | Downgrades | — | — | — | Jun 24, 2026 |
| TD Cowen | Hold | Downgrades | — | — | — | Jun 23, 2026 |
Annual Analyst Estimates
| Fiscal Year | Revenue Avg | Revenue Range | EPS Avg | EPS Range | Analysts |
|---|---|---|---|---|---|
| FY 2027 | $11.5M | — – — | — | — – — | — |
Want deeper AI-powered analysis?
Get BTI AI's full investment thesis, valuation models, and risk assessment for APGE.